{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.85","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"52.9","value":"35.8"},{"groupId":"OG001","lowerLimit":"-13.6","upperLimit":"58.2","value":"20.4"},{"groupId":"OG002","lowerLimit":"-25.9","upperLimit":"64.7","value":"28.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"P-FGF23 , change from baseline at 48 weeks.","dispersionType":"Inter-Quartile Range","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.","reportingStatus":"POSTED","timeFrame":"Change from baseline at 48 weeks reported.","title":"Percent Change From Baseline in P-fibroblast Growth Factor 23 (FGF23).","type":"SECONDARY","unitOfMeasure":"% change"}